Tirzepatide microdosing care comparison: match the offer to the evidence

CoreAge: a compounded longevity-oriented offer

CoreAge's tirzepatide description links dual-incretin activity with metabolic resilience and healthy aging. It explicitly identifies compounding and advertises questionnaire-based physician review. Those facts establish a public offer, not proof of the proposed longevity effects or an individual clinical recommendation.

Its shared landing page has a tirzepatide card at $129 monthly, qualified by twelve-month prepayment, while the dedicated page says $199. The separate $79 card is semaglutide. Our CoreAge review explains both the price boundary and why two receptor targets do not independently establish superiority over a different program.

SuperHealthy Rx: $199 one-month offer; confirm availability

The dedicated tirzepatide microdosing page lists $199 for a one-month supply and describes a clinician-reviewed low-dose program. The regular compounded tirzepatide promotional rate is a different offer and does not establish the cost of this program.

A public product description is not proof that every advertised intake is available in every state. Ask for current enrollment availability, the exact supplied preparation and written terms. Lower-dose or longevity language does not establish a standardized approved treatment regimen.

Read the SuperHealthy Rx review and official details.

3. Likeness Rx — GLP-1 weight care

The product name is a starting point for a care conversation. Likeness Rx offers online access to compounded semaglutide and tirzepatide. Its public page lists semaglutide from $79/month; tirzepatide from $129/month.

The lowest monthly equivalents accompany 12-month subscriptions: $948 for semaglutide or $1,548 for tirzepatide. One-month plans are $139 and $199. The page says the selected term renews automatically; check the amount due and cancellation date.

The public site describes licensed-provider review, shipping after approval and care-team messaging. Those are service statements rather than measured response times.

These are provider-published terms checked October 4, 2026. Prescription approval is conditional. Compounded medications are not FDA-approved; we have not tested the treatment, pharmacy fulfillment or patient outcomes.

Read our Likeness Rx review or the current product details.

Ivím: an explicit tirzepatide column and a separate program fee

Ivím's microdosing page separately lists compounded semaglutide and tirzepatide. The tirzepatide column shows monthly figures of $133, $149 and $200 for six-, four- and two-month options, with an additional $74.99 monthly program fee. The headline medicine figure therefore is not the whole advertised monthly cost.

The page describes a video consultation, continuing check-ins, app access and coaching. It also makes broader benefit and tolerability claims that need their own evidence. The Ivím review reads those claims alongside the site's explicit acknowledgment that compounded medicines are not FDA approved and individual assessment is required.

Noom: identify the Microdose Plus program precisely

The dedicated Noom support record identifies Microdose GLP-1Rx Plus as compounded tirzepatide. It distinguishes that offer from semaglutide Microdose and the separate non-microdose Plus program. It describes clinical messaging, coaching and behavioral tools, with location restrictions rather than universal availability.

Noom's cost explanation names the tirzepatide microdose option at $99 for the first four-week supply, then $597 per twelve weeks, displayed as $199 monthly. Our Noom review preserves the exact name and source qualification rather than assigning every general Microdose headline or outcome claim to this particular preparation.

Approved tirzepatide uses provide context, not a shortcut

The August 2026 Zepbound label covers specified adult weight-management and obstructive-sleep-apnea uses. The current Mounjaro label includes glycemic control for type 2 diabetes in adults and children aged ten and older, plus reduction of major cardiovascular events in adults with type 2 diabetes at high risk. These are distinct product and population records.

It would be inaccurate to say tirzepatide has no clinical-outcome evidence. It would also be inaccurate to transfer every approved use to a compounded wellness offer. Our sleep-apnea guide shows how to keep the disease, population, product and measured outcome connected without creating a personal eligibility assessment.

Mechanism and comparison evidence answer different questions

The receptor mechanism explains biological activity. It does not by itself quantify how much benefit one program provides, how often adverse effects occur or whether one person should receive it. The mechanism guide is therefore a starting point for understanding a claim, not a provider-scoring system.

A relevant comparative trial can answer a narrower question for its studied products and participants. The microdosing comparison-limits guide explains why that result cannot simply be assigned to these three commercial programs. Neither a shared ingredient nor the word individualized substitutes for evidence about the actual intervention being described.

Service features must connect to clinical responsibility

A video visit, messaging access and coaching are service descriptions. They do not prove that a specific new concern has reached a prescribing clinician or that a pharmacy record is complete. All three offers leave the actual assessment, proposed medicine and follow-up explanation to the professional relationship.

FDA's GLP-1 safety information describes errors and quality concerns with unapproved preparations. A review cannot turn those general warnings into a finding about one pharmacy, but it should not omit them. Discussion of the actual product, relevant contraindications, other medicines and monitoring of benefit and unwanted effects remains necessary even when a program emphasizes tolerability. Important label warnings include pancreatic and gallbladder concerns, serious gastrointestinal reactions and kidney injury from fluid loss. A provider’s support package is not a substitute for discussing those risks in clinical context.

The comparison should leave uncertainty visible

FDA's compounding FAQ distinguishes compounded drugs from approved generics. No website's professional credentials, facility language or subscription features establish approval of a particular compound. Nor does a change in an advertised metabolic marker automatically prove the broad healthspan benefit discussed in our biomarker guide.

This comparison verifies three publicly described tirzepatide microdosing offers and records their differences. It does not select a treatment, settle a personal quote or convert commercial order into clinical preference. The strongest answer a service can provide is a clear explanation of purpose, evidence, actual preparation and who will reassess the plan when circumstances change.

Read the wider field without making every service the same

The expanded directory covers different kinds of weight care. Found names tirzepatide in its broader catalog, while its dedicated microdose page names semaglutide. Fridays also needs that ingredient distinction. Amble explicitly discusses conditional compounded tirzepatide prescribing, whereas Eden names it conditionally in guarantee terms. A contract mention, general catalog and dedicated product page carry different amounts of information about an actual offer.

The directory also includes Amazon One Medical, whose reviewed pages establish broader primary-care weight management without confirming a named tirzepatide product, and DrHouse, whose clinical FAQ names Zepbound and Mounjaro as possible prescriptions. These are useful services to understand without treating them as identical microdosing programs. Follow the review that matches the question: what is named, what remains conditional, and which evidence addresses that exact proposal? A longer list improves the comparison only when those differences remain visible.